celecoxib has been researched along with Hematochezia in 36 studies
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a 67-year-old man taking a higher than usual dose of celecoxib (Celebrex) for osteoarthritis with resultant gastric erosions, ulceration, and a significant gastrointestinal (GI) hemorrhage." | 7.71 | Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. ( Crawford, AS; White, JG, 2002) |
| "A case history is described of a 38-year-old women, without digestive past, who presented with hemorrhagic ulcerated acute colitis beginning 2 days after starting celecoxib (200 mg/d) prescribed for sciatica." | 3.73 | [Ulcerating haemorrhagic colitis induced by celecoxib]. ( Andriamanantena, D; Carrère, C; Casassus-Builhè, D; Hamant, N; Perret, JL; Rey, P, 2005) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| " We describe a 67-year-old man taking a higher than usual dose of celecoxib (Celebrex) for osteoarthritis with resultant gastric erosions, ulceration, and a significant gastrointestinal (GI) hemorrhage." | 3.71 | Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. ( Crawford, AS; White, JG, 2002) |
| " Our patient had arthritis of the hips and chronic atrial fibrillation and was on warfarin therapy for stroke prevention; less than a week after starting celecoxib therapy, gastrointestinal bleeding and hypoprothrombinemia occurred." | 3.70 | Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. ( Davis, JV; Linder, JD; Mönkemüller, KE; Wilcox, CM, 2000) |
| "Celecoxib was associated with a lower risk of clinically significant upper and/or lower GI events than nsNSAIDs." | 2.78 | GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. ( Berger, MF; Cryer, B; Li, C; Simon, LS; Singh, G; Stillman, MJ, 2013) |
| "Celecoxib was predefined to be noninferior to placebo if the upper limit of the 95% CI for the hazard ratio (HR) with celecoxib was <1." | 2.77 | The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. ( Arber, N; Bertagnolli, MM; Coindreau, J; Eagle, C; Hawk, ET; Lanas, A; Levin, B; Lieberman, D; Sands, GH; Wang, TC; Zauber, A; Zhang, R, 2012) |
| "Treatment of celecoxib with a proton pump inhibitor is safer than treatment with nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and cardiovascular patients who mostly also take acetylsalicylic acid." | 2.52 | [Gastrointestinal bleeding]. ( Lanas, Á, 2015) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "Celecoxib without ASA was less likely than NS-NSAID without ASA to be associated with GI hospitalization [hazard ratio (HR) 0." | 1.34 | Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. ( Bardou, M; Barkun, AN; Dasgupta, K; Ghosn, J; Rahme, E; Toubouti, Y, 2007) |
| "Celecoxib has a superior upper-gastrointestinal (GI) safety profile compared with nonselective nonsteroidal antiinflammatory drugs (NS-NSAIDs)." | 1.34 | Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? ( Barkun, AN; Lelorier, J; Rahme, E; Rochon, S; Scalera, A; Toubouti, Y, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 25 (69.44) | 29.6817 |
| 2010's | 9 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onuora, S | 1 |
| de Melo, TR | 1 |
| Chelucci, RC | 1 |
| Pires, ME | 1 |
| Dutra, LA | 1 |
| Barbieri, KP | 1 |
| Bosquesi, PL | 1 |
| Trossini, GH | 1 |
| Chung, MC | 1 |
| dos Santos, JL | 1 |
| Lanas, Á | 3 |
| Hokuto, D | 1 |
| Nomi, T | 1 |
| Kawaguchi, C | 1 |
| Yoshikawa, T | 1 |
| Yasuda, S | 1 |
| Obara, S | 1 |
| Yamato, I | 1 |
| Yamada, T | 1 |
| Kanehiro, H | 1 |
| Nakajima, Y | 1 |
| Kellner, H | 1 |
| Rahme, E | 4 |
| Bernatsky, S | 1 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Arber, N | 1 |
| Lieberman, D | 1 |
| Wang, TC | 1 |
| Zhang, R | 1 |
| Sands, GH | 1 |
| Bertagnolli, MM | 1 |
| Hawk, ET | 1 |
| Eagle, C | 1 |
| Coindreau, J | 1 |
| Zauber, A | 1 |
| Levin, B | 1 |
| Thakkar, K | 1 |
| Fishman, DS | 1 |
| Gilger, MA | 1 |
| Cryer, B | 1 |
| Li, C | 1 |
| Simon, LS | 1 |
| Singh, G | 1 |
| Stillman, MJ | 1 |
| Berger, MF | 1 |
| Mamdani, M | 1 |
| Rochon, PA | 1 |
| Juurlink, DN | 1 |
| Kopp, A | 1 |
| Anderson, GM | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Beck, PL | 1 |
| Aspinall, AI | 1 |
| Kilvert, VM | 1 |
| Dort, J | 1 |
| Crawford, AS | 1 |
| White, JG | 1 |
| MacDonald, TM | 1 |
| Morant, SV | 1 |
| Goldstein, JL | 1 |
| Burke, TA | 1 |
| Pettitt, D | 1 |
| Oviedo, JA | 1 |
| Wolfe, MM | 1 |
| Serrano Pozo, A | 1 |
| Jara Palomares, L | 1 |
| Fuentes Rodríguez, F | 1 |
| Calderón Sandubete, E | 1 |
| Lamarque, D | 1 |
| Psaty, BM | 1 |
| Furberg, CD | 1 |
| Drazen, JM | 1 |
| Moride, Y | 1 |
| Ducruet, T | 1 |
| Boivin, JF | 1 |
| Moore, N | 1 |
| Perreault, S | 1 |
| Zhao, S | 1 |
| Rey, P | 1 |
| Andriamanantena, D | 1 |
| Carrère, C | 1 |
| Casassus-Builhè, D | 1 |
| Hamant, N | 1 |
| Perret, JL | 1 |
| Feczko, J | 1 |
| Underhill, JL | 1 |
| Bardou, M | 1 |
| Dasgupta, K | 1 |
| Toubouti, Y | 2 |
| Ghosn, J | 1 |
| Barkun, AN | 2 |
| Krzyzanowska, MK | 1 |
| Tannock, IF | 1 |
| Lockwood, G | 1 |
| Knox, J | 1 |
| Moore, M | 1 |
| Bjarnason, GA | 1 |
| Nedjar, H | 1 |
| Scalera, A | 1 |
| Rochon, S | 1 |
| Lelorier, J | 1 |
| Fidler, MJ | 1 |
| Argiris, A | 1 |
| Patel, JD | 1 |
| Johnson, DH | 1 |
| Sandler, A | 1 |
| Villaflor, VM | 1 |
| Coon, J | 1 |
| Buckingham, L | 1 |
| Kaiser, K | 1 |
| Basu, S | 1 |
| Bonomi, P | 1 |
| Mandell, BF | 1 |
| Linder, JD | 1 |
| Mönkemüller, KE | 1 |
| Davis, JV | 1 |
| Wilcox, CM | 1 |
| Moodley, I | 1 |
| Hirsch, G | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Brinker, AD | 1 |
| Bonnel, RA | 1 |
| Feight, AG | 1 |
| Nourjah, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In O[NCT00373685] | Phase 4 | 8,067 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00373685)
Timeframe: Baseline and Week 24 or ET
| Intervention | g/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -0.109 |
| nsNSAIDs | -0.241 |
(NCT00373685)
Timeframe: Baseline and Week 24 or ET
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.330 |
| nsNSAIDs | -0.716 |
(NCT00373685)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Celecoxib | 40.8 |
| nsNSAIDs | 40.9 |
(NCT00373685)
Timeframe: Baseline
| Intervention | gram per deciliter (g/dL) (Mean) |
|---|---|
| Celecoxib | 13.6 |
| nsNSAIDs | 13.6 |
GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 2.8 |
| nsNSAIDs | 3.0 |
CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin. (NCT00373685)
Timeframe: Baseline through week 24 or Early Termination (ET)
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 1.3 |
| nsNSAIDs | 2.4 |
"Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function." (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 2.3 |
| nsNSAIDs | 3.4 |
Positive blood fecal occult; blood in feces that is not visibly apparent (NCT00373685)
Timeframe: Week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 1.1 |
| nsNSAIDs | 1.4 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3888, 3905) | Week 8 (n=3185, 3203) | Week 16 (n=2783, 2778) | Week 24 or ET (n=3385, 3362) | Week 24/LOCF (n=3671, 3653) | |
| Celecoxib | 41.4 | 77.4 | 80.5 | 74.0 | 74.0 |
| nsNSAIDs | 40.5 | 69.2 | 74.5 | 71.3 | 70.8 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3886, 3905) | Week 8 (n=3182, 3202) | Week 16 (n=2780,2778) | Week 24 or ET (n=3383,3361) | Week 24/LOCF (n=3671, 3653) | |
| Celecoxib | 37.8 | 75.4 | 77.8 | 72.2 | 72.2 |
| nsNSAIDs | 36.6 | 66.8 | 71.6 | 68.8 | 68.2 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3890, 3905) | Week 8 (n=3185, 3202) | Week 16 (n=2784,2777) | Week 24 or ET (n=3386,3362) | Week 24/LOCF (n=3672, 3653) | |
| Celecoxib | 43.2 | 80.2 | 83.2 | 76.2 | 76.0 |
| nsNSAIDs | 43.7 | 71.6 | 77.7 | 73.8 | 73.3 |
Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3887, 3904) | Week 8 (n=3181, 3199) | Week 16 (n=2784, 2772) | Week 24 or ET (n=3383, 3361) | Week 24/LOCF (n=3672, 3651) | |
| Celecoxib | 39.8 | 78.5 | 81.9 | 74.6 | 74.5 |
| nsNSAIDs | 38.0 | 69.5 | 74.6 | 70.8 | 70.3 |
Clinically significant decrease in Hct (greater than or equal to 10 percent [≥10%]) and/or decrease in Hb (≥ 2 g/dL). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 8 (n= 3043, 3086) | Week 16 (n=2687, 2675) | Week 24 (n=3278, 3207) | Week 24 LOCF (n=3604, 3574) | |
| Celecoxib | 0.7 | 0.8 | 0.9 | 1.8 |
| nsNSAIDs | 0.9 | 1.6 | 1.5 | 2.9 |
Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use. (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Acetaminophen | Acetylsalicylic acid (ASA) | NSAIDs | Opioids | |
| Celecoxib | 6.8 | 3.5 | 12.8 | 14.2 |
| nsNSAIDs | 6.5 | 3.0 | 13.3 | 15.6 |
PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists [H2RA], misoprostol, sucralfate, and others such as antacids) utilization. (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| PPIs | H2RAs | Gastric protective agents | |
| Celecoxib | 23.0 | 5.0 | 0.9 |
| nsNSAIDs | 24.2 | 5.7 | 1.0 |
6 reviews available for celecoxib and Hematochezia
| Article | Year |
|---|---|
[Gastrointestinal bleeding].
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecox | 2015 |
Colorectal polyps in childhood.
Topics: Adenomatous Polyps; Adolescent; Age of Onset; Celecoxib; Child; Child, Preschool; Colonic Polyps; Co | 2012 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Di | 2003 |
COX 2-selective NSAIDs: biology, promises, and concerns.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Child; | 1999 |
Celecoxib--a rational alternative to NSAIDs.
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Drug Costs; | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
4 trials available for celecoxib and Hematochezia
| Article | Year |
|---|---|
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, | 2012 |
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibi | 2013 |
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2007 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell L | 2008 |
26 other studies available for celecoxib and Hematochezia
| Article | Year |
|---|---|
Therapy: Celecoxib reduces risk of ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Double-Blind Method; Gastrointestinal | 2017 |
Pharmacological evaluation and preparation of nonsteroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxyg | 2014 |
The Administration of Celecoxib as an Analgesic after Liver Resection Is Safe.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Celecoxib; Female; Gast | 2017 |
[Rheumatoid arthritis and depression].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressive Agents, Second- | 2009 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni | 2010 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2; Diclofen | 2002 |
Blue rubber bleb nevus syndrome.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colonic Diseases; Gastrointestina | 2002 |
Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Duodenal Ulcer; | 2002 |
[Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclo | 2003 |
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygen | 2003 |
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bias; Celecoxib; Cohort Studies; Databases, Factual; Family | 2003 |
[Lower gastrointestinal hemorrhage associated with celecoxib].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Femal | 2003 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ca | 2005 |
[Ulcerating haemorrhagic colitis induced by celecoxib].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Femal | 2005 |
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; | 2005 |
Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2005 |
Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase | 2007 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 I | 2007 |
Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Drug Antagoni | 2007 |
COX-2 inhibitors and Celebrex: safe or suspect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Atrial Fibrillation; Bicar | 2000 |
Celecoxib and rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemo | 2001 |